ACAD - ACADIA Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

ACAD is currently covered by 22 analysts with an average price target of $27.18. This is a potential upside of $6.2 (29.55%) from yesterday's end of day stock price of $20.98.

ACADIA Pharmaceuticals's activity chart (see below) currently has 373 price targets and 322 ratings on display. The stock rating distribution of ACAD is 68.13% BUY and 31.87% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 63.49% with an average time for these price targets to be met of 203.73 days.

Highest price target for ACAD is $37, Lowest price target is $20, average price target is $28.4.

Most recent stock forecast was given by JASON BUTLER from JMP on 25-Jun-2025. First documented stock forecast 05-May-2013.

Currently out of the existing stock ratings of ACAD, 62 are a BUY (68.13%), 29 are a HOLD (31.87%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$37

$16.02 (76.36%)

$42

18 days ago
(25-Jun-2025)

9/16 (56.25%)

$14.79 (66.59%)

238

Buy

$32

$11.02 (52.53%)

$32

18 days ago
(25-Jun-2025)

7/23 (30.43%)

$9.79 (44.08%)

118

Buy

$30

$9.02 (42.99%)

$30

18 days ago
(25-Jun-2025)

0/9 (0%)

$7.79 (35.07%)

Hold

$22

$1.02 (4.86%)

$19

18 days ago
(25-Jun-2025)

16/16 (100%)

$-0.21 (-0.95%)

89

Buy

$30

$9.02 (42.99%)

$25

1 months 8 days ago
(05-Jun-2025)

5/9 (55.56%)

$8.02 (36.49%)

26

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is ACAD (ACADIA Pharmaceuticals) average time for price targets to be met?

On average it took 203.73 days on average for the stock forecasts to be realized with a an average price target met ratio 63.49

Which analyst has the current highest performing score on ACAD (ACADIA Pharmaceuticals) with a proven track record?

CORY KASIMOV

Which analyst has the most public recommendations on ACAD (ACADIA Pharmaceuticals)?

Cory Kasimov works at EVERCORE and has 8 price targets and 6 ratings on ACAD

Which analyst is the currently most bullish on ACAD (ACADIA Pharmaceuticals)?

Alan Carr with highest potential upside - $39.02

Which analyst is the currently most reserved on ACAD (ACADIA Pharmaceuticals)?

Salveen Richter with lowest potential downside - -$8.98

ACADIA Pharmaceuticals in the News

Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 10%. A quarter ago, it was expected that...

Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

Acadia Pharmaceuticals ACAD reported first-quarter 2025 earnings of 11 cents per share, which beat the Zacks Consensus Estimate of 10 cents. In the year-ago quarter, the company had reported earnings of 10 cents per share. Acadia recorded total revenues of $244.3 million, which surpassed the Zacks Consensus Estimate of $241 million. ACAD’s net product revenues...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?